Tiong Kit Tan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1795215/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	13.5	788
2	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nature Structural and Molecular Biology, 2020, 27, 846-854.	3.6	434
3	The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, 2021, 184, 2183-2200.e22.	13.5	331
4	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host and Microbe, 2020, 28, 445-454.e6.	5.1	298
5	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature Structural and Molecular Biology, 2020, 27, 950-958.	3.6	268
6	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nature Communications, 2021, 12, 542.	5.8	200
7	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	5.8	150
8	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science, 2022, 377, .	6.0	120
9	An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature Immunology, 2022, 23, 50-61.	7.0	110
10	Adenosine-to-inosine editing of endogenous Z-form RNA by the deaminase ADAR1 prevents spontaneous MAVS-dependent type I interferon responses. Immunity, 2021, 54, 1961-1975.e5.	6.6	69
11	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathogens, 2021, 17, e1009352.	2.1	56
12	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	5.8	54
13	Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med, 2021, 2, 164-179.e12.	2.2	53
14	Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation. Angewandte Chemie - International Edition, 2021, 60, 321-330.	7.2	45
15	Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nature Communications, 2021, 12, 4617.	5.8	44
16	Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites. Immunity, 2022, 55, 718-733.e8.	6.6	44
17	The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. IScience, 2021, 24, 103144.	1.9	34
18	Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans. Journal of Virology, 2020, 94, .	1.5	29

TIONG KIT TAN

#	Article	IF	CITATIONS
19	A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy. MAbs, 2020, 12, 1804241.	2.6	28
20	Inclusion of cGAMP within virusâ€like particle vaccines enhances their immunogenicity. EMBO Reports, 2021, 22, e52447.	2.0	24
21	Pathogen-sugar interactions revealed by universal saturation transfer analysis. Science, 2022, 377, .	6.0	24
22	Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell–cell fusion. Journal of General Virology, 2021, 102, .	1.3	21
23	Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS†CoV†2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients. International Journal of Infectious Diseases, 2021, 109, 85-89.	1.5	18
24	SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly. Nature Communications, 2022, 13, .	5.8	12
25	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Scientific Reports, 2022, 12, 1727.	1.6	11
26	Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation. Angewandte Chemie, 2021, 133, 325-334.	1.6	8
27	Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. Frontiers in Public Health, 2021, 9, 724398.	1.3	8
28	Lung-targeting lentiviral vector for passive immunisation against influenza. Thorax, 2020, 75, 1112-1115.	2.7	7
29	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Theranostics, 2022, 12, 1-17.	4.6	6
30	Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals. Immunity, Inflammation and Disease, 2022, 10, e592.	1.3	6
31	Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka. Journal of Immunology, 2021, 207, 2681-2687.	0.4	4
32	An improved method for the rescue of recombinant Newcastle disease virus. BioTechniques, 2020, 68, 96-100.	0.8	3
33	Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. Clinical and Experimental Immunology, 2022, 208, 323-331.	1.1	3
34	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
35	Development of a T7 RNA polymerase expressing cell line using lentivirus vectors for the recovery of recombinant Newcastle disease virus. Journal of Virological Methods, 2021, 291, 114099.	1.0	0